MYRRHINIL-INTEST® Überzogene Tabletten 100 mg Myrrhe
Sponsors
REPHA GmbH Biologische Arzneimittel
Conditions
Diarrhoea predominant irritable bowel syndrome
Phase 4
Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type irritable bowel syndrome (IBS-M)
RecruitingCTIS2024-514892-16-00
Start: 2020-05-05Target: 268Updated: 2025-10-13
Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D)
RecruitingCTIS2024-514383-61-00
Start: 2020-07-07Target: 220Updated: 2025-10-13